Bioventus, Inc. (BVS)

Q: What's priced into Bioventus, Inc. (BVS) stock?

The valuation evidence is mixed: BVS is described as cheap versus peers, while the model also shows a 61% premium to peers and an expectations gap of -0.21. Overall, pricing is tagged as justified with low fragility, but confidence in that reading is medium and the evidence does not clearly define what expectations the market has already embedded.

Q: What does the Bioventus, Inc. (BVS) outlook hinge on?

Over the next few quarters, the thesis depends on management maintaining guidance and turning revenue growth into stronger earnings and cash flow. The view would be pressured by a guidance cut or worsening employment conditions, while continued earnings strength from healthcare peers could support the sector backdrop. Litigation is an additional risk, but the snapshot provides limited detail about its potential effect.

NASDAQHealth CareMedical - DevicesSnapshot 2026-10-23

$14.96-0.53%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Bioventus, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	169.96M
EPS	—	0.237
FY 2026 · Annual
Revenue	$600M–$610M	604.79M
EPS	$0.75–$0.79non-GAAP	0.779
Operating cash flow	$84M–$89M	—
FY 2027 · Annual
Revenue	—	645.58M
EPS	—	0.92

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Adjusted EPS at or above $0.75 in 2026	A primary condition in Bioventus, Inc.'s published investment case. The stated target is >=0.75 USD per share.	Intact	Adjusted EPS falls below $0.75 in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Cash from operations at or above $84 million in 2026	Cash from operations guidance was raised to $84M-$89M, showing improving cash flow.	Intact	Cash from operations falls below $84 million in FY26	Cash from operations: $19.873M FY2026-Q2; GAAP. Published target: >=84 million USD. Target period is not explicitly aligned with this observation. Source published Aug 5, 202619,873,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 27, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue at or above $600 million in 2026	A primary condition in Bioventus, Inc.'s published investment case. The stated target is >=600 million USD.	Intact	Revenue falls below $600 million in FY26	Revenue: $153.208M FY2026-Q2; GAAP. Published target: >=600 million USD. Target period is not explicitly aligned with this observation. Source published Aug 5, 2026153,208,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 27, 2026 Source: company_financial_results. Reference: 3ed914fc-3a16-4672-8278-438a12f1cf62. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. The Company has consistently reaffirmed full-year 2026 guidance with net sales expected between $600M and $610M, adjusted EPS of $0.75 to $0.79, and cash from operations of $84M to $89M. Revenue grew from $132.1M in 2026-Q1 to $153.2M in 2026-Q2, supporting the guidance. The trajectory is delivering as management maintains stable guidance amid revenue growth. Delivery assessment Oct 24, 2026
Maintain PE ratio below peer median of 36.5	A supporting condition in Bioventus, Inc.'s published investment case. The stated target is <=36.5 PE.	Intact	PE ratio rises above 36.5	P/E (TTM): 19.68x As of 2026-10-23; trailing twelve months. The target timing and basis require a separate assessment. Market data as of Oct 23, 202619.6842 ratio · calculatedLast status assessment Oct 24, 2026 Measurement source consolidated · TTM valuation Period ending Oct 23, 2026 Source: mart.stock_valuation_daily. Reference: BVS:2026-10-23. Source status: canonical calculation. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPSUnavailable

$0.91 → Unavailable · observed estimates

FY2027 revenueUnavailable

$0.65B → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$0.91	$646,276,400	5 / 5
2026-07-25	$0.91	$646,276,400	5 / 5
2026-07-26	$0.91	$646,276,400	5 / 5
2026-07-27	$0.91	$646,276,400	5 / 5
2026-07-28	$0.91	$646,276,400	5 / 5
2026-07-29	$0.91	$646,276,400	5 / 5
2026-07-30	$0.91	$646,276,400	5 / 5
2026-07-31	Unavailable	Unavailable	4 / 4
2026-08-01	Unavailable	Unavailable	4 / 4
2026-08-02	$0.91	$646,276,400	5 / 5
2026-08-03	$0.91	$646,276,400	5 / 5
2026-08-04	$0.91	$646,276,400	5 / 5
2026-08-05	$0.91	$646,276,400	5 / 5
2026-08-06	$0.91	$646,276,400	5 / 5
2026-08-07	Unavailable	Unavailable	3 / 4
2026-08-08	Unavailable	Unavailable	3 / 4
2026-08-09	$0.91	$645,329,600	5 / 5
2026-08-10	Unavailable	Unavailable	3 / 4
2026-08-11	$0.91	$645,329,600	5 / 5
2026-08-12	$0.91	$645,329,600	5 / 5
2026-08-13	Unavailable	Unavailable	3 / 4
2026-08-14	Unavailable	Unavailable	3 / 4
2026-08-15	Unavailable	Unavailable	3 / 4
2026-08-16	Unavailable	Unavailable	3 / 4
2026-08-17	Unavailable	Unavailable	3 / 4
2026-08-18	Unavailable	Unavailable	3 / 4
2026-08-19	Unavailable	Unavailable	3 / 4
2026-08-20	Unavailable	Unavailable	4 / 4
2026-08-21	Unavailable	Unavailable	4 / 4
2026-08-22	Unavailable	Unavailable	4 / 4
2026-08-23	Unavailable	Unavailable	4 / 4
2026-08-24	Unavailable	Unavailable	4 / 4
2026-08-25	Unavailable	Unavailable	4 / 4
2026-08-26	Unavailable	Unavailable	4 / 4
2026-08-27	Unavailable	Unavailable	4 / 4
2026-08-28	Unavailable	Unavailable	4 / 4
2026-08-29	Unavailable	Unavailable	4 / 4
2026-08-30	Unavailable	Unavailable	4 / 4
2026-08-31	Unavailable	Unavailable	4 / 4
2026-09-01	Unavailable	Unavailable	4 / 4
2026-09-02	Unavailable	Unavailable	4 / 4
2026-09-03	Unavailable	Unavailable	4 / 4
2026-09-04	Unavailable	Unavailable	4 / 4
2026-09-05	Unavailable	Unavailable	4 / 4
2026-09-06	Unavailable	Unavailable	4 / 4
2026-09-07	Unavailable	Unavailable	4 / 4
2026-09-08	Unavailable	Unavailable	4 / 4
2026-09-09	Unavailable	Unavailable	4 / 4
2026-09-10	Unavailable	Unavailable	4 / 4
2026-09-11	Unavailable	Unavailable	4 / 4
2026-09-12	Unavailable	Unavailable	4 / 4
2026-09-13	Unavailable	Unavailable	4 / 4
2026-09-14	Unavailable	Unavailable	4 / 4
2026-09-15	Unavailable	Unavailable	4 / 4
2026-09-16	Unavailable	Unavailable	4 / 4
2026-09-17	Unavailable	Unavailable	4 / 4
2026-09-18	Unavailable	Unavailable	4 / 4
2026-09-19	Unavailable	Unavailable	4 / 4
2026-09-20	Unavailable	Unavailable	4 / 4
2026-09-21	Unavailable	Unavailable	4 / 4
2026-09-22	Unavailable	Unavailable	4 / 4
2026-09-23	Unavailable	Unavailable	4 / 4
2026-09-24	Unavailable	Unavailable	4 / 4
2026-09-25	Unavailable	Unavailable	4 / 4
2026-09-26	Unavailable	Unavailable	4 / 4
2026-09-27	Unavailable	Unavailable	4 / 4
2026-09-28	Unavailable	Unavailable	4 / 4
2026-09-29	Unavailable	Unavailable	4 / 4
2026-09-30	Unavailable	Unavailable	4 / 4
2026-10-01	Unavailable	Unavailable	4 / 4
2026-10-02	Unavailable	Unavailable	4 / 4
2026-10-03	Unavailable	Unavailable	4 / 4
2026-10-04	Unavailable	Unavailable	4 / 4
2026-10-05	Unavailable	Unavailable	4 / 4
2026-10-06	Unavailable	Unavailable	4 / 4
2026-10-07	Unavailable	Unavailable	4 / 4
2026-10-08	Unavailable	Unavailable	4 / 4
2026-10-09	Unavailable	Unavailable	4 / 4
2026-10-10	Unavailable	Unavailable	4 / 4
2026-10-11	Unavailable	Unavailable	4 / 4
2026-10-12	Unavailable	Unavailable	4 / 4
2026-10-13	Unavailable	Unavailable	4 / 4
2026-10-14	Unavailable	Unavailable	4 / 4
2026-10-15	Unavailable	Unavailable	4 / 4
2026-10-16	Unavailable	Unavailable	4 / 4
2026-10-17	Unavailable	Unavailable	4 / 4
2026-10-18	Unavailable	Unavailable	4 / 4
2026-10-19	Unavailable	Unavailable	4 / 4
2026-10-20	Unavailable	Unavailable	4 / 4
2026-10-21	Unavailable	Unavailable	4 / 4
2026-10-22	Unavailable	Unavailable	4 / 4
2026-10-23	Unavailable	Unavailable	4 / 4
2026-10-24	Unavailable	Unavailable	4 / 4

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	5	0	0
2026-06-01	5	0	0
2026-07-01	5	0	0
2026-08-01	5	0	0
2026-09-01	5	0	0
2026-10-01	5	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 5 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Adjusted EPS at or above $0.75 in 2026Direct metric needs a verified mapping
Cash from operations at or above $84 million in 2026Cash from operations: $19.873M
Revenue at or above $600 million in 2026Revenue: $153.208M
Maintain PE ratio below peer median of 36.5P/E (TTM): 19.68x

Next proof point

Nov 3, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.2%Typical daily move · historical

Downside history

-27.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Bioventus, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

BVS is a higher-risk growth and execution story, not yet a proven profitable compounder. The long-term thesis is intact, supported by strong recent performance and a healthcare-sector tailwind, but earnings quality remains weak because the company is loss-making.

What's priced into Bioventus, Inc.

The valuation evidence is mixed: BVS is described as cheap versus peers, while the model also shows a 61% premium to peers and an expectations gap of -0.21. Overall, pricing is tagged as justified with low fragility, but confidence in that reading is medium and the evidence does not clearly define what expectations the market has already embedded.

What the fundamentals likely do

Near term, revenue growth and management’s repeated reaffirmation of 2026 guidance support the current operating trajectory. Pain Treatments grew in the second quarter, and debt prepayments have reduced long-term debt, though progress on that priority remains under watch. Risks include a possible guidance cut, weakening jobs data, and recently filed litigation; the latest earnings report was in line.

What Bioventus, Inc. hinges on

Over the next few quarters, the thesis depends on management maintaining guidance and turning revenue growth into stronger earnings and cash flow. The view would be pressured by a guidance cut or worsening employment conditions, while continued earnings strength from healthcare peers could support the sector backdrop. Litigation is an additional risk, but the snapshot provides limited detail about its potential effect.

Bottom line

For the 1-to-3-year view, BVS has a supportive growth and sector setup, but its loss-making profile and elevated risks make execution central to the thesis. Not investment advice.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	169.96M
EPS	—	0.237
FY 2026 · Annual
Revenue	$600M–$610M	604.79M
EPS	$0.75–$0.79non-GAAP	0.779
Operating cash flow	$84M–$89M	—
FY 2027 · Annual
Revenue	—	645.58M
EPS	—	0.92

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPSUnavailable

$0.91 → Unavailable · observed estimates

FY2027 revenueUnavailable

$0.65B → Unavailable · observed estimates

Exact estimates & source dates

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$0.91	$646,276,400	5 / 5
2026-07-25	$0.91	$646,276,400	5 / 5
2026-07-26	$0.91	$646,276,400	5 / 5
2026-07-27	$0.91	$646,276,400	5 / 5
2026-07-28	$0.91	$646,276,400	5 / 5
2026-07-29	$0.91	$646,276,400	5 / 5
2026-07-30	$0.91	$646,276,400	5 / 5
2026-07-31	Unavailable	Unavailable	4 / 4
2026-08-01	Unavailable	Unavailable	4 / 4
2026-08-02	$0.91	$646,276,400	5 / 5
2026-08-03	$0.91	$646,276,400	5 / 5
2026-08-04	$0.91	$646,276,400	5 / 5
2026-08-05	$0.91	$646,276,400	5 / 5
2026-08-06	$0.91	$646,276,400	5 / 5
2026-08-07	Unavailable	Unavailable	3 / 4
2026-08-08	Unavailable	Unavailable	3 / 4
2026-08-09	$0.91	$645,329,600	5 / 5
2026-08-10	Unavailable	Unavailable	3 / 4
2026-08-11	$0.91	$645,329,600	5 / 5
2026-08-12	$0.91	$645,329,600	5 / 5
2026-08-13	Unavailable	Unavailable	3 / 4
2026-08-14	Unavailable	Unavailable	3 / 4
2026-08-15	Unavailable	Unavailable	3 / 4
2026-08-16	Unavailable	Unavailable	3 / 4
2026-08-17	Unavailable	Unavailable	3 / 4
2026-08-18	Unavailable	Unavailable	3 / 4
2026-08-19	Unavailable	Unavailable	3 / 4
2026-08-20	Unavailable	Unavailable	4 / 4
2026-08-21	Unavailable	Unavailable	4 / 4
2026-08-22	Unavailable	Unavailable	4 / 4
2026-08-23	Unavailable	Unavailable	4 / 4
2026-08-24	Unavailable	Unavailable	4 / 4
2026-08-25	Unavailable	Unavailable	4 / 4
2026-08-26	Unavailable	Unavailable	4 / 4
2026-08-27	Unavailable	Unavailable	4 / 4
2026-08-28	Unavailable	Unavailable	4 / 4
2026-08-29	Unavailable	Unavailable	4 / 4
2026-08-30	Unavailable	Unavailable	4 / 4
2026-08-31	Unavailable	Unavailable	4 / 4
2026-09-01	Unavailable	Unavailable	4 / 4
2026-09-02	Unavailable	Unavailable	4 / 4
2026-09-03	Unavailable	Unavailable	4 / 4
2026-09-04	Unavailable	Unavailable	4 / 4
2026-09-05	Unavailable	Unavailable	4 / 4
2026-09-06	Unavailable	Unavailable	4 / 4
2026-09-07	Unavailable	Unavailable	4 / 4
2026-09-08	Unavailable	Unavailable	4 / 4
2026-09-09	Unavailable	Unavailable	4 / 4
2026-09-10	Unavailable	Unavailable	4 / 4
2026-09-11	Unavailable	Unavailable	4 / 4
2026-09-12	Unavailable	Unavailable	4 / 4
2026-09-13	Unavailable	Unavailable	4 / 4
2026-09-14	Unavailable	Unavailable	4 / 4
2026-09-15	Unavailable	Unavailable	4 / 4
2026-09-16	Unavailable	Unavailable	4 / 4
2026-09-17	Unavailable	Unavailable	4 / 4
2026-09-18	Unavailable	Unavailable	4 / 4
2026-09-19	Unavailable	Unavailable	4 / 4
2026-09-20	Unavailable	Unavailable	4 / 4
2026-09-21	Unavailable	Unavailable	4 / 4
2026-09-22	Unavailable	Unavailable	4 / 4
2026-09-23	Unavailable	Unavailable	4 / 4
2026-09-24	Unavailable	Unavailable	4 / 4
2026-09-25	Unavailable	Unavailable	4 / 4
2026-09-26	Unavailable	Unavailable	4 / 4
2026-09-27	Unavailable	Unavailable	4 / 4
2026-09-28	Unavailable	Unavailable	4 / 4
2026-09-29	Unavailable	Unavailable	4 / 4
2026-09-30	Unavailable	Unavailable	4 / 4
2026-10-01	Unavailable	Unavailable	4 / 4
2026-10-02	Unavailable	Unavailable	4 / 4
2026-10-03	Unavailable	Unavailable	4 / 4
2026-10-04	Unavailable	Unavailable	4 / 4
2026-10-05	Unavailable	Unavailable	4 / 4
2026-10-06	Unavailable	Unavailable	4 / 4
2026-10-07	Unavailable	Unavailable	4 / 4
2026-10-08	Unavailable	Unavailable	4 / 4
2026-10-09	Unavailable	Unavailable	4 / 4
2026-10-10	Unavailable	Unavailable	4 / 4
2026-10-11	Unavailable	Unavailable	4 / 4
2026-10-12	Unavailable	Unavailable	4 / 4
2026-10-13	Unavailable	Unavailable	4 / 4
2026-10-14	Unavailable	Unavailable	4 / 4
2026-10-15	Unavailable	Unavailable	4 / 4
2026-10-16	Unavailable	Unavailable	4 / 4
2026-10-17	Unavailable	Unavailable	4 / 4
2026-10-18	Unavailable	Unavailable	4 / 4
2026-10-19	Unavailable	Unavailable	4 / 4
2026-10-20	Unavailable	Unavailable	4 / 4
2026-10-21	Unavailable	Unavailable	4 / 4
2026-10-22	Unavailable	Unavailable	4 / 4
2026-10-23	Unavailable	Unavailable	4 / 4
2026-10-24	Unavailable	Unavailable	4 / 4

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings